Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reduced Systemic Absorption with High-Dose Delgocitinib Cream in Adults with Severe Chronic Hand Eczema: Findings from the DELTA 2 Phase 3 Randomized, Double-Blind, Vehicle-Controlled Trial

  • By

  • Melinda Gooderham

  • Christopher G. Bunick

  • JiaDe Yu

  • Douglas Maslin

  • Shannon K. R. Schneider

  • Marie Louise Østerdal

  • Anders Søhoel

  • Daniel Elenius Madsen

  • Lawrence F. Eichenfield

  • May 17, 2026

Share

Original Source(s)

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

  • by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield

  • May 17, 2026

Related Content

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management

Earlier Egg Intake Linked to Less Allergy

Population-based data suggest uptake of updated feeding recommendations coincided with modest declines in egg allergy prevalence, particularly among infants with early eczema.